Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Zikani Therapeutics, a US-based rare disease therapy developer spun out of Harvard University, closed a $7.5m series A1 round on Monday that involved Roche Venture Fund, the corporate venturing unit of pharmaceutical firm Roche, venture firm Advent Life Sciences and healthcare-focused fund Gurnet Point Capital. The series A1 capital is expected to support the optimisation of lead molecules that use ribosome modulation to treat rare genetic diseases such as class 1 cystic fibrosis and a mutation-driven variant of colon cancer.…
